Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542969 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
A Phase 1 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02542969 is a Phase 1 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT02542969, a Phase 1 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether MGL-3196 alters the pharmacokinetics of rosuvastatin and/or simvastatin in healthy male subjects and female subjects not of child-bearing potential.
Interventions
- DRUG Rosuvastatin
- DRUG Simvastatin
- DRUG MGL-3196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542969
The ClinicalTrials.gov registry entry for NCT02542969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosuvastatin is the first listed.
NCT02542969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542969 about?
NCT02542969 is a clinical study titled "Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin". The purpose of this study is to determine whether MGL-3196 alters the pharmacokinetics of rosuvastatin and/or simvastatin in healthy male subjects and female subjects not of child-bearing potential.
What is the current status of trial NCT02542969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02542969?
The interventions under investigation include: Rosuvastatin (DRUG), Simvastatin (DRUG), MGL-3196 (DRUG).
Who is sponsoring clinical trial NCT02542969?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.